Search

Your search keyword '"Na, Kook Joo"' showing total 269 results
Start Over Author "Na, Kook Joo"
269 results on '"Na, Kook Joo"'

6. Genetic Variant of Notch Regulator DTX1 Predicts Survival After Lung Cancer Surgery

Author

Lee, Jang Hyuck, Shin, Kyung Min, Lee, Shin Yup, Hong, Mi Jeong, Choi, Jin Eun, Kang, Hyo-Gyoung, Do, Sook Kyung, Lee, Won Kee, Lee, Eung Bae, Seok, Yangki, Jeong, Ji Yun, Yoo, Seung Soo, Lee, Jaehee, Cha, Seung Ick, Kim, Chang Ho, Cho, Sukki, Jheon, Sanghoon, Kim, Young Chul, Oh, In Jae, Na, Kook Joo, Kim, Moon Soo, Lee, Jong Mog, Yang, Hee Chul, Jung, Chi Young, Park, Chang Kwon, Lee, Min Ki, Kim, Dong Kwan, and Park, Jae Yong

Published
2019
Full Text
View/download PDF

7. Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical Resection.

Author

Park, Hwa Kyung, Choi, Yoo Duk, Yun, Ju-Sik, Song, Sang-Yun, Na, Kook-Joo, Yoon, Joon Young, Yoon, Chang-Seok, Oh, Hyung-Joo, Kim, Young-Chul, and Oh, In-Jae

Subjects
LUNG cancer, ADENOCARCINOMA, EPITHELIAL cell tumors, GENETIC mutation, CONFIDENCE intervals, EPIDERMAL growth factor receptors, ONCOGENES, CANCER relapse, RETROSPECTIVE studies, ACQUISITION of data, CANCER patients, RISK assessment, COMPARATIVE studies, MEDICAL records, DESCRIPTIVE statistics, RESEARCH funding, DISEASE risk factors, DISEASE complications
Abstract

Simple Summary: We investigated the prevalence of genetic alterations and their association with epidermal growth factor receptor (EGFR) mutations and prognosis in early-stage non-small cell lung cancer (NSCLC) after curative resection. The results showed that the prevalence of EGFR mutations, anaplastic lymphoma kinase (ALK) rearrangements, and ROS proto-oncogene 1 (ROS1) fusion were 43.0%, 5.7%, and 1.6%, respectively. Patients with EGFR-mutant NSCLC had a higher risk of recurrence than those without EGFR mutations. Additionally, EGFR mutations were related to a high proportion of distant metastases and a higher risk of central nervous system recurrence. A definitive surgical resection is the preferred treatment for early-stage non-small cell lung cancer (NSCLC). Research on genetic alterations, including epidermal growth factor receptor (EGFR) mutations, in early-stage NSCLC remains insufficient. We investigated the prevalence of genetic alterations in early-stage NSCLC and the association between EGFR mutations and recurrence after a complete resection. Between January 2019 and December 2021, 659 patients with NSCLC who underwent curative surgical resections at a single regional cancer center in Korea were recruited. We retrospectively compared the clinical and pathological data between the recurrence and non-recurrence groups. Among the 659 enrolled cases, the median age was 65.86 years old and the most common histology was adenocarcinoma (74.5%), followed by squamous cell carcinoma (21.7%). The prevalence of EGFR mutations was 43% (194/451). Among them, L858R point mutations and exon 19 deletions were 52.3% and 42%, respectively. Anaplastic lymphoma kinase (ALK) rearrangement was found in 5.7% of patients (26/453) and ROS proto-oncogene 1 (ROS1) fusion was found in 1.6% (7/441). The recurrence rate for the entire population was 19.7%. In the multivariate analysis, the presence of EGFR mutations (hazard ratio (HR): 2.698; 95% CI: 1.458–4.993; p = 0.002), stage II (HR: 2.614; 95% CI: 1.29–5.295; p = 0.008) or III disease (HR: 9.537; 95% CI: 4.825–18.852; p < 0.001) (vs. stage I disease), and the presence of a pathologic solid type (HR: 2.598; 95% CI: 1.405–4.803; p = 0.002) were associated with recurrence. Among the recurrence group, 86.5% of the patients with EGFR mutations experienced distant metastases compared with only 66.7% of the wild type (p = 0.016), with no significant difference in median disease-free survival (52.21 months vs. not reached; p = 0.983). In conclusion, adjuvant or neoadjuvant targeted therapy could be considered more actively because EGFR mutations were identified as an independent risk factor for recurrence and were associated with systemic recurrence. Further studies on perioperative therapy for other genetic alterations are necessary. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Recurrence Risk-Scoring Model for Stage I Adenocarcinoma of the Lung

Author

Yang, Hee Chul, Kim, Hyeong Ryul, Jheon, Sanghoon, Kim, Kwhanmien, Cho, Sukki, Ahn, Soyeon, Lee, Ho-Young, Chung, Jin-Haeng, Chung, Kyung Young, Bae, Mi Kyung, Park, Seong Yong, Kim, Dong Kwan, Choi, Se Hoon, Zo, Jae Ill, Kim, Moon Soo, Lee, Jong Mog, Kim, Jhingook, Shim, Young Mog, Na, Kook Joo, Yun, Ju Sik, and Park, Jae Yong

Published
2015
Full Text
View/download PDF

14. Integrated genomic analysis of recurrence-associated small non-coding RNAs in oesophageal cancer

Author

Jang, Hee-Jin, Lee, Hyun-Sung, Burt, Bryan M, Lee, Geon Kook, Yoon, Kyong-Ah, Park, Yun-Yong, Sohn, Bo Hwa, Kim, Sang Bae, Kim, Moon Soo, Lee, Jong Mog, Joo, Jungnam, Kim, Sang Cheol, Yun, Ju Sik, Na, Kook Joo, Choi, Yoon-La, Park, Jong-Lyul, Kim, Seon-Young, Lee, Yong Sun, Han, Leng, Liang, Han, Mak, Duncan, Burks, Jared K, Zo, Jae Ill, Sugarbaker, David J, Shim, Young Mog, and Lee, Ju-Seog

Published
2017
Full Text
View/download PDF

17. Treatment outcomes of elective neck dissection in intrathoracic esophageal carcinoma.

Author

Lee, Dong Hoon, Lee, Dae-Neung, Jang, Hye-Bin, Lee, Joon Kyoo, Lim, Sang Chul, Yun, Ju Sik, and Na, Kook Joo

Subjects
NECK dissection, TREATMENT effectiveness, SQUAMOUS cell carcinoma, LYMPHADENECTOMY, ESOPHAGEAL cancer, CARCINOMA
Abstract

In the present study, the outcomes of elective neck dissection in patients with intrathoracic esophageal squamous cell carcinoma were investigated. From January 2016 to December 2022, 21 patients who underwent esophagectomy and elective neck dissection (both neck level IV) for intrathoracic esophageal squamous cell carcinoma were enrolled. Of these 21 patients, 19 patients were male and 2 were female. A total of 11 patients received concurrent chemoradiotherapy (CCRT) as preoperative treatment. As a result of elective neck dissection at both neck level IV, occult neck metastasis of esophageal squamous cell carcinoma was diagnosed in 3 cases, all of which involved left neck lymph nodes. The incidence of occult neck metastasis was statistically significant in patients with preoperative CCRT, high T stage and high N stage (P<0.05). In addition, 16 out of 21 patients had been under follow-up without disease recurrence after the completion of treatment. However, 3 out of 21 patients succumbed to esophageal squamous cell carcinoma and 2 out of 21 patients were alive with stable disease of esophageal carcinoma. The follow-up period was 19.2±18.4 months. In conclusion, three-field lymph node dissection for intrathoracic esophageal squamous cell carcinoma may be necessary in patients with certain phenotypes, such that collaboration between thoracic surgeons and otolaryngologists may help reduce surgical complications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial

Author

Shim, Young Mog, primary, Yun, Jeonghee, additional, Im, Young-Hyuck, additional, Lee, Genehee, additional, Kang, Danbee, additional, Cho, Juhee, additional, Kim, Kwhanmien, additional, Park, Seung-Il, additional, Na, Kook Joo, additional, Kim, Sung-bae, additional, and Zo, Jae Ill, additional

Published
2021
Full Text
View/download PDF

25. Artificial intelligence and lung cancer treatment decision: agreement with recommendation of multidisciplinary tumor board

Author

Kim, Min-Seok, primary, Park, Ha-Young, additional, Kho, Bo-Gun, additional, Park, Cheol-Kyu, additional, Oh, In-Jae, additional, Kim, Young-Chul, additional, Kim, Seok, additional, Yun, Ju-Sik, additional, Song, Sang-Yun, additional, Na, Kook-Joo, additional, Jeong, Jae-Uk, additional, Yoon, Mee Sun, additional, Ahn, Sung-Ja, additional, Yoo, Su Woong, additional, Kang, Sae-Ryung, additional, Kwon, Seong Young, additional, Bom, Hee-Seung, additional, Jang, Woo-Youl, additional, Kim, In-Young, additional, Lee, Jong-Eun, additional, Jeong, Won-Gi, additional, Kim, Yun-Hyeon, additional, Lee, Taebum, additional, and Choi, Yoo-Duk, additional

Published
2020
Full Text
View/download PDF

28. Primary pulmonary myxoid sarcoma located in interlobar fissure without parenchymal invasion

Author

Kim, Seok, Song, Sang Yun, Yun, Ju Sik, Choi, Yoo Duk, and Na, Kook Joo

Subjects
thoracoscopy/VATS, pulmonary, Myxoid sarcoma, Case Report, Case Reports
Abstract

Primary pulmonary myxoid sarcoma (PPMS), classified as low to intermediate grade malignant myxoid endobronchial tumor, is rarely reported. Most reported cases occurred in lung parenchyme with an endobronchial component. Herein, we report a case of PPMS in a 29‐year‐old woman that developed in a major fissure of the left lung without parenchymal invasion. Histopathologically, the diagnosis was compatible to PPMS with EWSR1‐CREB1 translocation.

Published
2017

29. Development of a prognosis‐prediction model incorporating genetic polymorphism with pathologic stage in stage I non‐small cell lung cancer: A multicenter study

Author

Lee, Won Kee, Lee, Shin Yup, Choi, Jin Eun, Seok, Yangki, Lee, Eung Bae, Lee, Hyun Cheol, Kang, Hyo‐Gyoung, Yoo, Seung Soo, Lee, Myung Hoon, Cho, Sukki, Jheon, Sanghoon, Kim, Young Chul, Oh, In Jae, Na, Kook Joo, Jung, Chi Young, Park, Chang‐Kwon, Kim, Mi‐Hyun, Lee, Min Ki, and Park, Jae Yong

Subjects
Adult, Male, Genotype, Original Articles, Kaplan-Meier Estimate, Middle Aged, NSCLC, Prognosis, stage, Polymorphism, Single Nucleotide, Disease-Free Survival, polymorphism, surgery, Chemotherapy, Adjuvant, Risk Factors, Carcinoma, Non-Small-Cell Lung, Humans, Original Article, Aged, Neoplasm Staging
Abstract

Background This multicenter study was performed to develop a prognosis‐prediction model incorporating genetic polymorphism with pathologic stage for surgically treated non‐small cell lung cancer (NSCLC) patients. Methods A replication study including 720 patients and a panel of eight single nucleotide polymorphisms (SNPs), which predicted the prognosis of surgically treated NSCLC in our previous study, was conducted. Using the combined cohort of current and previous studies including 1534 patients, a nomogram for predicting overall survival was made using Cox proportional hazards regression. Results Among the eight SNPs, C3 rs2287845, GNB2L1 (alias RACK1), and rs3756585 were significantly associated with overall survival. A nomogram was constructed based on pathologic stage and the genotypes of the two SNPs, and the risk score was calculated for each patient in the combined cohort. Using the prognosis‐prediction model, we categorized patients into low, intermediate, and high‐risk groups, which had greater accuracy in predictive ability (log‐rank statistics = 54.66) than the conventional tumor node metastasis staging (log‐rank statistics = 39.56). Next, we generated a prognosis‐prediction model for stage I to identify a subgroup of potential candidates for adjuvant chemotherapy. Notably, 97 out of 499 stage IB patients were classified as high‐risk patients with a similar prognosis to stage II patients, suggesting the benefit of adjuvant chemotherapy. Conclusions This prognosis‐prediction model incorporating genetic polymorphism with pathologic stage may lead to more precise prognostication in surgically resected NSCLC patients. In particular, this model may be useful in selecting a subgroup of stage IB patients who may benefit from adjuvant chemotherapy.

Published
2017

30. efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.

Author

Shim, Young Mog, Yun, Jeonghee, Im, Young-Hyuck, Lee, Genehee, Kang, Danbee, Cho, Juhee, Kim, Kwhanmien, Park, Seung-Il, Na, Kook Joo, Kim, Sung-bae, and Zo, Jae Ill

Subjects
ADJUVANT chemotherapy, SQUAMOUS cell carcinoma, CISPLATIN, RANDOMIZED controlled trials, CHEMORADIOTHERAPY, PROGRESSION-free survival, TUMOR classification
Abstract

There is limited evidence for the effectiveness of adjuvant chemotherapy in esophageal squamous cell carcinoma (ESCC). This study aimed to assess whether adjuvant capecitabine and cisplatin improve survival compared to surgery alone among patients with locally advanced ESCC. This is a multicenter randomized controlled trial. Patients were eligible if they underwent curative resection for ESCC staged T2–4 or N1 and M0 according to the TNM cancer staging system sixth edition. The intervention group received four cycles of adjuvant chemotherapy (capecitabine: 1,000 mg/m 2 b.i.d for 14 days, and intravenous cisplatin: 75 mg/m2 at day 1, every 3 weeks). A total of 136 patients were randomly assigned to either the adjuvant chemotherapy group (n  = 68) or surgery-alone group (n  = 68). Seven patients who rejected chemotherapy after randomization were excluded from the final analysis. The cumulative incidence of recurrence within 18 months after surgery was significantly lower in the adjuvant chemotherapy group than in the surgery-alone group (hazard ratio [HR]: 0.49; 95% confidence interval (CI): 0.25–0.95]. However, the 5- and 10-year disease-free survival did not differ between treatment groups (HR: 0.84; 95% CI: 0.53–1.34 and HR: 0.76; 95% CI: 0.50–1.18, respectively). Adjuvant chemotherapy after curative resection in patients with locally advanced ESCC reduced early recurrence but had no statistically significant increase in the long-term disease-free survival. Due to the limited sample size of this study, additional randomized controlled trials with larger sample sizes are necessary. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. Laparoscopic repair of hiatal hernia

Author

Yun, Ju Sik, primary, Na, Kook Joo, additional, Song, Sang Yun, additional, Kim, Seok, additional, Kim, Eunchong, additional, Jeong, In Seok, additional, and Oh, Sang Gi, additional

Published
2019
Full Text
View/download PDF

41. Regulatory variants in cancer-related pathway genes predict survival of patients with surgically resected non-small cell lung cancer

Author

Shin, Kyung Min, primary, Hong, Mi Jeong, additional, Lee, Shin Yup, additional, Jin, Cheng Cheng, additional, Baek, Sun Ah, additional, Lee, Jang Hyuck, additional, Choi, Jin Eun, additional, Kang, Hyo-Gyoung, additional, Lee, Won Kee, additional, Seok, Yangki, additional, Lee, Eung Bae, additional, Jeong, Ji Yun, additional, Yoo, Seung Soo, additional, Lee, Jaehee, additional, Cha, Seung Ick, additional, Kim, Chang Ho, additional, Kim, Young Chul, additional, Oh, In Jae, additional, Na, Kook Joo, additional, Cho, Sukki, additional, Jheon, Sanghoon, additional, and Park, Jae Yong, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results